H-1B sponsorship profile: Glenmark Pharmaceuticals, Inc USA. Across U.S. Department of Labor LCA disclosures, Glenmark Pharmaceuticals, Inc USA filed 17 Labor Condition Applications covering 17 H-1B worker positions between fiscal year 2023 and fiscal year 2026. The employer’s DOL certification rate sits at 94.1% (16 certified of 17 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Glenmark Pharmaceuticals, Inc USA’s H-1B petitions range from $105,000 at the low end to $315,000 at the high end, with a petition-weighted average of $161,819. That range reflects the mix of occupations the company sponsors, led by Validation Specialist (2 petitions at $109,211 avg), followed by Site Quality Head and Senior Director “ Quality, North America. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Glenmark Pharmaceuticals, Inc USA is headquartered in Mahwah, NJ under NAICS code 424210, and places H-1B workers across 2 states, most heavily in NC, NJ. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Glenmark Pharmaceuticals, Inc USA ranks. By H-1B petition volume, Glenmark Pharmaceuticals, Inc USA is #11,465 of 119,880 employers nationally and #1,056 of 5,818 employers headquartered in NJ. Both ranks are computed live from the same underlying petition counts, not a separate estimate.